Alnuctamab

Phase 3Monoclonal antibody

Bristol-Myers Squibb

Alnuctamab is one of 55 small molecule programs targeting Multiple Myeloma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaWithdrawn

RefractoryRecruiting

Multiple MyelomaPhase 3

Withdrawn

RefractoryPhase 1

Recruiting

Competition

Competitive Landscape

258 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

39 2

Empliciti

Bristol-Myers Squibb

Phase 3

43 3

TALVEY

Johnson & Johnson

Phase 3

22 4

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 5

Opdivo

Bristol-Myers Squibb

Phase 3

11 6

Vepesid

AAvyxa

Phase 3

17 7

Etentamig

AbbVie

Phase 3

8 8

Daratumumab SC

Johnson & Johnson

Phase 3

5 9

Velcade

AZD0120

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Refractory

NCT07219563

Q3 2028

Phase 1Recruiting

Multiple Myeloma

NCT06121843

Clinical

Trials by Indication[1]

Multiple Myeloma3 trials

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06163898·156 enrolled

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06232707

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT06121843·187 enrolled

Refractory1 trial

Alnuctamab for Refractory SLE (LATTE Study)

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT07219563·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Alnuctamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alnuctamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alnuctamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Alnuctamab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Trials by Indication[1]

Multiple Myeloma3 trials

Refractory1 trial

References

Drug Info

Quick Facts

Related News